Subscribe To
Cti biopharma to present at the 43rd annual cowen health care conference
SEATTLE , March 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and comm...
March 1, 2023, 4:20 pm
Cardiff oncology to present at the cowen 43rd annual health care conference
SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a ...
February 27, 2023, 8:15 am
Black diamond therapeutics to present at the cowen 43rd annual health care conference
CAMBRIDGE, Mass. and NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology ...
February 27, 2023, 8:00 am
Cti biopharma to report fourth quarter and full year 2022 financial results and provide corporate update on monday, march 6, 2023
SEATTLE , Feb. 23, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and com...
February 23, 2023, 7:03 am
Plus therapeutics to announce fourth quarter and full year 2022 financial results and host conference call on february 23, 2023
AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company ...
February 14, 2023, 7:00 am
Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...
February 13, 2023, 5:00 pm
Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...
February 13, 2023, 5:00 pm
Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...
February 13, 2023, 5:00 pm
Biotech's drug pipeline expands from melanoma to other cancers
Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March....
February 13, 2023, 1:50 pm
Blueprint's (bpmc) cancer study put on partial hold by fda
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers...
February 13, 2023, 1:33 pm
Erasca: potential strong upside ahead
Erasca, Inc. is a clinical-stage biopharmaceutical developer of therapies for patients with RAS/MAPK pathway-driven ...
February 8, 2023, 11:21 am
Hillstream biopharma to host virtual r&d day to showcase its emerging immuno-oncology pipeline targeting drug-resistant cancers
Quatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs) by inducing ferroptosis in drug resistant
February 6, 2023, 12:00 pm
: the perils of ultraprocessed food
A growing body of research links ultraprocessed foods to an array of cancers and, in some cases, to cog...
February 4, 2023, 11:18 am
Revolution medicines to participate in upcoming investor conferences
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing target...
February 2, 2023, 7:00 am
Erasca to present at the guggenheim oncology conference 2023
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoverin...
February 1, 2023, 8:00 am
Correction — bellicum reports inducement grants under nasdaq listing rule 5635(c)(4)
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) — In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the to...
January 31, 2023, 11:43 pm
Context therapeutics says clinical partner stemline therapeutics receives fda approval for orserdu to treat certain breast cancers
Context Therapeutics (NASDAQ:CNTX) has announced that its clinical trial collaborator, Stemline Therapeutics Inc, a wholly-owned subsidiary of The Me...
January 31, 2023, 8:33 am
Aim immunotech shares rise on news of pancreatic cancer research partnership with astrazeneca and erasmus medical center
AIM ImmunoTech Inc (NYSE:AIM) (AIM) announced that it has entered into an external sponsored collaborative clinical research agreement with AstraZene...
January 17, 2023, 10:26 am
Omega therapeutics to present trial-in-progress poster for phase 1/2 mychelangelo™ i study at the american society of clinical oncology gastrointestinal cancers symposium
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pion...
January 17, 2023, 7:00 am
Context therapeutics announces manufacturing agreement with lonza for bispecific antibody targeting claudin 6 positive cancers
Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech...
January 9, 2023, 9:03 am